Why the Imugene (ASX:IMU) share price advanced 5% on market open

Imugene is bolstering its intellectual property portfolio.

| More on:
A drawing of a rocket follows a chart up, indicating share price lift

Image source: Getty Images

Key points

  • Imugene share price soared 5% on the back of European patent approval
  • This is further intellectual protection for the company’s HER-Vaxx immunotherapy
  • Today’s news follows recent South Korean patent award

Imugene Limited (ASX: IMU) shares were on the move at the open this morning, soaring 5% to 30 cents before quickly retreating in the first hour of trading.

At the time of writing, the Imugene share price is down 1.75% to 28 cents apiece. It’s worth noting that Imugene was heavily sold off in the past week, with the share price falling by roughly 20%.

Let’s take a look at the news that the immuno-oncology company released this morning.

Imugene achieves another ‘important milestone’

Investors initially bid the Imugene share price up today, following a positive announcement and a rebound across the ASX.

The All Ordinaries (ASX: XAO) is travelling 0.4% higher to 7,146 points, after spending this week deep in the red.

According to the Imugene release, management advised it has received a notice of grant from the European Patent Office. This is in relation to the company’s HER-Vaxx immunotherapy, which is in development for HER-2 positive gastric cancer.

Earlier this month, Imugene also secured patent approval from the South Korean Intellectual Property Office for the same therapy.

HER-Vaxx immunotherapy is a B-cell activating immunotherapy. The therapy treats tumours that over-express the HER-2/neu receptor. Imugene is designing HER-Vaxx to treat gastric, breast, ovarian, lung, and pancreatic cancers.

This patent approval in a major oncology market is a key step in protecting the company’s intellectual property.

The patent protects the method of composition and method of use of Imugene’s HER-Vaxx immunotherapy for 15 years.

Imugene managing director and CEO, Leslie Chong said:

Attaining the key European patent is an important milestone and is another major pharmaceutical market to grant patent protection for HER-Vaxx until 2036.

Imugene share price summary

It has been a solid 12 months for Imugene investors, with the company’s share price jumping 156%. The share price reached an all-time high of 62.5 cents in November before embarking on a downhill trend.

Imugene presides a market capitalisation of roughly $1.65 billion with approximately 5.81 billion shares on issue.

Should you invest $1,000 in Imugene right now?

Before you consider Imugene, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Imugene wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Growth Shares

Why CSL shares are ‘going to deliver’ in 2022: fund manager

Quality growth companies can perform well even in an era of rising interest rates.

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Incannex share price pops 9% on FDA news

The medicinal cannabis drug development company came out with some positive developments from its FDA meeting...

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

What’s going on with the Polynovo share price today?

The strong start has dissipated for Polynovo shares.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Virtus share price holds steady despite 30% earnings fall

Shareholders are staying loyal with a looming acquisition.

Read more »

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance
Healthcare Shares

Own Medibank shares? Here’s what to watch over the coming months

What are the key dates for Medibank in 2022?

Read more »